All-or-Nothing Biotech Bets Dented by Rising Treasury Yields

Published on October 22, 2026

Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.

Continue reading on website
Other news

As AI Expands, the Standard for Human Advice Must Rise

October 22, 2026
What clients should reasonably expect from a professional when technology can perform more of the foundational work itself.

Apple Is Wall Street’s Favorite AI Haven as Spending Fears Hit

October 22, 2026
It’s become one of the most reliable trades in the stock market as sentiment toward artificial intelligence swings wildly: Whatever AI stocks do, Apple Inc. does the opposite.